Question of Dose, Fractionation and Technique: Ingredients for Testing Hypofractionation in Prostate Cancer - the CHHiP Trial

Clinical Oncology

Volumn 20, Issue 1, 2008, Pages 12-14

  Khoo, V S ^a   Dearnaley, D P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER CONTROL; CLINICAL TRIAL; EDITORIAL; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECTUM DISEASE; TREATMENT OUTCOME;

DOSE FRACTIONATION; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; PROSTATIC NEOPLASMS; RADIOTHERAPY, HIGH-ENERGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 38149102436     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.10.008     Document Type: Editorial

References (21)

1. Khoo V.S., and Joon D.L. New developments in MRI for target volume delineation in radiotherapy. Br J Radiol 79 (2006) S2-S15
2. Dearnaley D.P., Khoo V.S., Norman A.R., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353 9149 (1999) 267-272
3. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 5 (2002) 1097-1105
4. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92 3 (2005) 488-498
5. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 10 (2005) 1233-1239
6. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 13 (2006) 1990-1996
7. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 6 (2007) 475-487
8. Beckendorf V., Guerif S., Le Prise E., et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 60 4 (2004) 1056-1065
9. Khoo V.S. Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clin Oncol (R Coll Radiol) 17 7 (2005) 560-571
10. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 5 (2002) 1111-1116
11. Fowler J., Chappell R., and Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 4 (2001) 1021-1031
12. Brenner D.J., Martinez A.A., Edmundson G.K., Mitchell C., Thames H.D., and Armour E.P. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 1 (2002) 6-13
13. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol (R Coll Radiol) 19 5 (2007) 289-301
14. Williams S.G., Taylor J.M., Liu N., et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68 1 (2007) 24-33
15. Hoskin P.J., and Dearnaley D.P. Hypofractionation in clinical trials for prostate cancer. Clin Oncol (R Coll Radiol) 19 5 (2007) 287-288
16. Livsey J.E., Cowan R.A., Wylie J.P., et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 57 5 (2003) 1254-1259
17. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66 4 (2006) 1072-1083
18. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 25 (2005) 6132-6138
19. Bentzen S.M., and Ritter M.A. The alpha/beta ratio for prostate cancer: what is it, really?. Radiother Oncol 76 1 (2005) 1-3
20. South C., Khoo V.S., Naismith O., Norman A., and Dearnaley D.P. A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol) 20 1 (2007) 15-21
21. Dearnaley D, Norman A, Syndikus I, et al. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHIP) - a phase III multicentre trial. Preliminary report on acute and late toxicity (ISRCTN97182923). The 2007 Multidisciplinary Prostate Cancer Symposium, 2007, Orlando, Florida. American Society of Clinical Oncology (ASCO) Program/Proceedings [abstract 303].